Clinical Trials

Pfizer and Merck’s avelumab fails to improve OS or PFS in Javelin ovarian cancer trial

Pfizer and Merck have announced that avelumab alone or in combination with pegylated liposomal doxorubicin (PLD) has failed to improve overall survival (OS) or progression-free survival (PFS) rate in phase III Javelin Ovarian 200 trial.

GlycoMimetics enrolls first patient in Phase III clinical trial of uproleselan

GlycoMimetics has dosed the first patient in its Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory acute myeloid leukemia (AML).

AstraZeneca’s Imfinzi fails to improve OS in Mystic lung cancer trial

AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.

Seattle Genetics begins blood cancer trial with SEA-BCMA

Seattle Genetics has dosed the d first patient in a phase 1 clinical trial evaluating the safety and tolerability of SEA-BCMA for patients with relapsed or refractory multiple myeloma (MM).

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.

AbbVie’s Mavyret shows high virologic cure rates in HCV study

AbbVie’s Mavyret (glecaprevir/pibrentasvir) has showed high virologic cure rates in treatment-naïve patients with compensated cirrhosis in the phase 3b Expedition-8 study.

Gilead’s GS-9674 shows positive action in primary sclerosing cholangitis

Gilead Sciences announced that its GS-9674 has showed significant improvements in liver biochemistry and markers of cholestasis in patients with primary sclerosing cholangitis (PSC) in a phase 2 trial.

Visterra begins phase 1 clinical study of monoclonal antibody VIS649

Clinical stage biotechnology firm Visterra has commenced a phase 1 clinical study of VIS649 in healthy volunteers.

4D pharma begins patient enrollment in Blautix IBS phase II study

UK-based 4D pharma has commenced patient enrollment for a phase 2 clinical trial to evaluate its single-strain live biotherapeutic candidate Blautix to treat Irritable Bowel Syndrome (IBS).